PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Our offering

At Evolve, we provide specialised IP strategy services tailored to the unique needs of pharmaceutical and biotechnology companies at every stage of development. Our approach combines scientific expertise with commercial insight to deliver practical intellectual property solutions that drive business value. We understand that effective IP strategy must be both deeply rooted in the science and adapt alongside your company’s growth.

With extensive industry experience and technical knowledge, we are passionate about supporting our clients to realise the full potential of their innovations.

 

Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional in-house

Do you need experienced IP leadership without the overhead of a full-time in-house team?

Our fractional in-house service delivers the senior head of IP expertise you require on a flexible and cost-effective basis, allowing you to scale your IP function precisely when and how you need it. We understand the critical role intellectual property plays in your growth and offer a tailored approach to align your IP strategy directly with your overarching business objectives. Our fractional in-house service seamlessly integrates with your existing team, becoming a trusted partner in managing your day-to-day IP needs. By working with us you will benefit from strategically managed intellectual property helping you to foster innovation, secure investment and gain a competitive edge.

With Evolve you access experienced IP leadership when you need it. Think of us as your dedicated, senior IP resource, readily available to handle the operational complexities while providing expert strategic direction.

Find out more

Sectors

Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.

 

Find out more
  • Pharmaceuticals
  • Biotech
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • Chemistry

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more

IP strategy for the universal cell therapy revolution

  • 27th August 2025
The cell therapy landscape is at a pivotal moment. There is a considerable pressure within the industry to solve the manufacturing and logistical challenges that have defined the first generation of cell therapies.

Divergence between the UPC and EPO on claim interpretation and description definitions (Agfa v Gucci, UPC_CFI_278/2023)

  • 12th August 2025
A new ruling in Agfa v Gucci reveals a split between the UPC and the EPO on claim interpretation, with the UPC using a patent’s own ‘lexicon’ to narrow a claim, a decision with major implications for patent holders in Europe.

The great consolidation: Big pharma buys the advanced therapy technology, not just the drug

  • 8th August 2025
The latest cell and gene therapy industry trends reveals a shift in strategy towards platforms.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.

The reproducibility challenge for advanced therapies (T 0827/23)

  • 4th August 2025
Your biotech invention works, but can you prove it’s better? A recent EPO ruling on extracellular vesicles (T 0827/23) shows why the lack of comparative data can be fatal for a patent.

Referral on description amendments finally confirmed (G1/25 – “Hydroponics”)

  • 29th July 2025
At last, the wait is over. After years of conflicting case law and mounting frustration for practitioners, the Enlarged Board of Appeal is set to rule on the controversial issue of description amendments in G1/25. But will the decision actually bring clarity?

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2025 All Rights Reserved

Keep in touch

Subscribe

Contact Us